Innovation

Oxygen Depletion Method

GENELUVIÉ's oxygen depletion method was developed to minimise oxygen exposure and suppress oxidative pathways through advanced oxygen-control processes.

By reducing oxygen burden and avoiding aggressive solvent systems, the oxygen depletion method helps maintain molecular integrity while preserving formulation elegance and clarity.

Features

OXYGEN DEPLETION FEATURES

  • Oxygen-Controlled Processing
  • Solvent-Free Stabilisation
  • No Propylene Glycol
  • No Polyethylene Glycols (PEGs)
  • No Ethanol-Based Carriers
  • No Harsh Solvent-Dependent Preservatives
  • Reactive Oxygen Species (ROS) Suppression
  • Swiss Manufacturing Standards

Technologies

GENELUVIÉ Technologies

Oxygen Depletion

Advanced oxygen-control processing that minimises oxidative exposure and preserves molecular integrity.

SwissCraft™ Manufacturing

Precision-engineered production protocols adhering to rigorous Swiss pharmaceutical standards.

PureMatrix™ Vehicle System

A clean, elegant delivery platform formulated without harsh solvents, PEGs, or propylene glycol.

NanoLipid™ Encapsulation

Proprietary NanoLipid™ Encapsulation sheaths each peptide molecule in a precision-calibrated phospholipid bilayer vesicle, creating a biomimetic shield against oxidative stress, thermal degradation, and enzymatic breakdown while enhancing bioavailability through cellular membrane fusion.

Molecular Architecture

Nano Lipid Encapsulation Technology

At GENELUVIÉ, we deploy proprietary NanoLipid™ Encapsulation — a molecular-scale delivery architecture that individually sheaths each peptide molecule within a precision-calibrated phospholipid bilayer vesicle. This nanoscale engineering operates at dimensions between 50 and 200 nanometers, creating a biomimetic microenvironment that mirrors natural cellular membrane structures. Within this protected lipid envelope, delicate peptide chains are shielded from reactive oxygen species, thermal fluctuation, enzymatic hydrolysis, and pH-mediated conformational destabilization — preserving their native tertiary structure and full pharmacological potency from synthesis through administration.

The encapsulation process demands extraordinary precision. Our lipid-to-peptide ratios are calculated to microgram accuracy, with hydration parameters, sonication amplitude, and extrusion pressures monitored in real time across multiple process control points. Each batch undergoes dynamic light scattering analysis to confirm monodisperse particle size distribution, zeta potential measurement to verify surface charge stability, and cryo-transmission electron microscopy to validate vesicle morphology. A deviation of even 0.5% in lipid composition or 2°C in processing temperature can alter vesicle lamellarity and compromise encapsulation efficiency — which is why our Swiss manufacturing facilities maintain atmospheric conditions within ISO 5 cleanroom specifications throughout the entire production cascade.

By encasing peptides within these nano lipid carriers, we achieve markedly enhanced shelf stability — extending peak binding affinity preservation from months to years under refrigerated conditions — while simultaneously creating a protective barrier against environmental degradation during global transport and variable storage conditions. The lipid bilayer facilitates passive fusion with cellular membranes, improving bioavailability and ensuring that the therapeutic payload reaches target tissues with the structural fidelity our molecular architects intended.

This is not merely formulation science — it is molecular guardianship at the nanometer scale. Every vesicle is a testament to our conviction that protecting the molecule is as critical as engineering it. When you choose GENELUVIÉ, you are choosing a brand that treats each peptide with the reverence of a master craftsman, because we believe that exceptional care at the molecular level translates directly into exceptional outcomes for the people who trust us with their wellbeing.